Literature DB >> 29332991

Prospective HIV Clinical Trial Comparison by Expected Kullback-Leibler Divergence.

LaMont Cannon1, Cesar Augusto Vargas Garcia2, Michael J Piovoso2, Ryan Zurakowski1,2.   

Abstract

The sample frequency and volume of blood that can be drawn from a single patient is meticulously restricted under the human subject protection protocols established by an institutional review board (IRB). Consequently, the amount of samples that can be taken during a particular experiment is limited. In order to ensure an effective experiment design, considerations must be taken choosing when to take patient samples. A validated model of HIV-1 viral replication and 2-LTR production is exploited to find sub-optimal sampling schedules that maximize information content of the experiment outcome. This is done through a Forward Stepwise Regression (FSR) process with Kullback Liebler Divergence (KLD) as a selection criterion. Suboptimal schedules are found for an experiment taking four sample points over a possible span of 20 weeks. All schedules found with the FSR process contain significantly more information than both a uniform schedule and a schedule used in a previous experiment with 4 sample points. This work demonstrates the advantages of using KLD as a tool in the experiment design process to increase information content.

Entities:  

Year:  2016        PMID: 29332991      PMCID: PMC5761735          DOI: 10.1109/ACC.2016.7525096

Source DB:  PubMed          Journal:  Proc Am Control Conf        ISSN: 0743-1619


  11 in total

1.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Authors:  H Hatano; S Vogel; C Yoder; J A Metcalf; R Dewar; R T Davey; M A Polis
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Re-emergence of HIV after stopping therapy.

Authors:  T W Chun; R T Davey; D Engel; H C Lane; A S Fauci
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

4.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.

Authors:  Deborah Persaud; George K Siberry; Aima Ahonkhai; Joleen Kajdas; Daphne Monie; Nancy Hutton; Douglas C Watson; Thomas C Quinn; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Authors:  Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-08-23       Impact factor: 5.226

8.  HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.

Authors:  Rutao Luo; Michael J Piovoso; Javier Martinez-Picado; Ryan Zurakowski
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Authors:  Rutao Luo; E Fabian Cardozo; Michael J Piovoso; Hulin Wu; Maria J Buzon; Javier Martinez-Picado; Ryan Zurakowski
Journal:  J R Soc Interface       Date:  2013-05-08       Impact factor: 4.118

10.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

View more
  4 in total

1.  Implications of Measurement Assay Type in Design of HIV Experiments.

Authors:  LaMont Cannon; Aditya Jagarapu; Cesar A Vargas-Garcia; Michael J Piovoso; Ryan Zurakowski
Journal:  Proc IEEE Conf Decis Control       Date:  2018-01-23

2.  HIV 2-LTR experiment design optimization.

Authors:  LaMont Cannon; Cesar A Vargas-Garcia; Aditya Jagarapu; Michael J Piovoso; Ryan Zurakowski
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

3.  Analysis of Cell Signal Transduction Based on Kullback-Leibler Divergence: Channel Capacity and Conservation of Its Production Rate during Cascade.

Authors:  Tatsuaki Tsuruyama
Journal:  Entropy (Basel)       Date:  2018-06-05       Impact factor: 2.524

4.  Epidermal growth factor receptor cascade prioritizes the maximization of signal transduction.

Authors:  Kaori Kiso-Farnè; Tatsuaki Tsuruyama
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.